Abstract
Graft-versus-host disease (GvHD) in its acute and chronic forms continues to represent a significant barrier to the success and wide-applicability of blood and marrow transplantation as a potentially curative treatment modality for a number of benign and malignant blood conditions. Presently, calcineurin inhibitor (CNI)-based regimens remain the most commonly used prevention strategy, although post-transplant cyclophosphamide is emerging as an alternative approach, and is providing a backbone for innovative CNI-free combinations. In this paper, we review the current strategies used for the prevention of GvHD, and highlight some of the developing and promising combinations.
Article PDF
Avoid common mistakes on your manuscript.
References
Remberger, M, Ackefors, M, Berglund, S, Blennow, O, Dahllöf, G, Dlugosz, A, et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single center study. Biol Blood Marrow Tranplant 2011;17;1688–97.
Woolfrey, A, Lee, SJ, Gooley, TA, Malkki, M, Martin, PJ, Pagel, JM, et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant 2010;16;1382–7.
Arai, S, Arora, M, Wang, T, Spellman, SR, He, W, Couriel, DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21;266–74.
Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011;117;6963–70.
Bacigalupo, A, Van Lint, MT, Occhini, D, Gualandi, F, Lamparelli, T, Sogno, G, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77;1423–8.
Ruutu, T, van Biezen, A, Hertenstein, B, Henseler, A, Garderet, L, Passweg, J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47;1459–64.
Ferrara, JL, Levy, R, Chao, NJ. Pathophysiologic mechanisms of acute graft-versus-host disease. Biol Blood Marrow Transplant 1999;5;347–56.
Welniak, LA, Blazar, BR, Murphy, WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Ann Rev Immunol 2007;25;139–70.
Loiseau, P, Busson, M, Balere, ML, Dormoy, A, Bignon, JD, Gagne, K, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007;13; 965–74.
Chao, NJ. Minors come of age: minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant 2004;10;215–23.
Reddy, P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003;21;149–61.
Matzinger, P. The danger model: a renewed sense of self. Science 2002;296;301–5.
Xun, CQ, Thompson, JS, Jennings, CD, Brown, SA, Widmer, MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994;83;2360–7.
Remberger, M, Jaksch, M, Uzunel, M, Mattsson, J. Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. Eur J Haematol 2003;70;384–91.
Fowler, DH, Foley, J, Whit-Shan Hou, J, Odom, J, Castro, K, Steinberg, SM, et al. Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol 2004;2;237–45.
Zeiser, R, Blazar, BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. NEJM 2017;377;2565–79.
Crocchiolo, R, Ciceri, F, Fleischhauer, K, Oneto, R, Bruno, B, Pollichieni, S, et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant 2009;44;571–7.
Flowers, MED, Inamoto, Y, Carpenter, PA, Lee, SJ, Kiem H-P, Petersdorf, EW, et al. Comaprative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Intitues of Health consensu criteria. Blood 2011;117;3214–19.
Jagasia, M, Arora, M, Flowers, ME, Chao, NJ, McCarthy, PL, Cutler, CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;5;296–307.
Storb, R, Deeg, HJ, Whitehead, J, Appelbaum, F, Beatty, P, Bensinger, W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314;729–35.
Ratanatharathorn, V, Nash, RA, Przepiorka, D, Devine, SM, Klein, JL, Weisdorf, D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92;2303–14.
Nash, RA, Antin, JH, Karanes, C, Fay, JW, Avalos, BR, Yeager, AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96;2062–8.
Hamilton, BK, Bolwell, BJ, Kalaycio, M, Rybicki, L, Hanna, R, Sobecks, R, et al. Long-term follow-up of a randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for graft versus host disease prophylaxis in myeloablative HLA-identical sibling hematopoietic cell transplantation. Blood 2012;120;3073.
Hamilton, BK, Liu, Y, Hemmer, M, Wang, T, Chhabra, S, Costa, LJ, et al. Cyclosporine in combination with mycophenolate mofetil leads to increased incidence of graft-versus-host disease and inferior outcomes after myeloablative Aalogeneic hematopoietic cell transplantation: a CIBMTR Analysis. Biol Blood Marrow Transplant 2018;24;S185.
Chhabra, S, Liu, Y, Hemmer, MT, Costa, L, Pidala, JA, Couriel, DR, et al. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant 2019;25;73–85.
Cutler, C, Logan, B, Nakamura, R, Johnston, L, Choi, S, Porter, D, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014;124;1372–7.
Ho, VT, Aldridge, J, Kim, HT, Cutler, C, Koreth, J, Armand, P, et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009;15;844–50.
Koreth, J, Kim, HT, Lange, PB, Poryanda, SJ, Reynolds, CG, Rai, SC, et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica 2018; 103;522–30.
Choi, SW, Braun, T, Henig, I, Gatza, E, Magenau, J, Parkin, B, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD following myeloablative conditioning unrelated donor HCT. Blood 2017;130;1760–7.
Reshef, R,Luger, SM, Hexner, EO,Loren, AW, Frey, NV, Nasta,SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012;367;135–45.
Reynolds, J, Shojania, K, Marra, CA. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy 2007;27;1693–701.
Koura, DT, Horan, JT, Langston, AA, Qayed, M, Mehta, A, Khoury, HJ, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant 2013;19;1638–49.
Finke, J, Bethge, WA, Schmoor, C, Ottinger, HD, Stelljes, M, Zander, AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10;855–64.
Socie, G, Schmoor, C, Bethge, WA, Ottinger, HD, Stelljes, M, Zander, AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117;6375–82.
Kröger, N, Solano, C, Wolschke, C, Bandini, G, Patriarca, F, Pini, M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016;374;43–53.
Walker, I, Panzarella, T, Couban, S, Couture, F, Devins, G, Elemary, M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 2016;17;164–73.
Soiffer, RJ, Kim, HT, McGuirk, J, Horwitz, ME, Johnston, L, Patnaik, MM, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 2017;35;4003–11.
Kumar, A, Reljic, T, Hamadani, M, Mohty, M, Kharfan-Dabaja, MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant 2019;54;1094–106.
Jenkins, MK, Schwartz, RH, Pardoll, DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241;1655–8.
Appelbaum, FR. Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. Best Pract Res Clin Haematol 2007;20;67–75.
Holtan, SG, Pasquini, M, Weisdorf, DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014;124;363–73.
Malard, F, Szydlo, RM, Brissot, E, Chevallier, P, Guillaume, T, Delaunay, J, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010;16;28–34.
Al-Kadhimi, Z, Gul, Z, Chen, W, Smith, D, Abidi, M, Deol, A, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biol Blood Marrow Transplant 2014;20;979–85.
Touzot, M, Elie, C, van Massenhove, J, Maillard, N, Buzyn, A, Fakhouri, F. Long-term renal function after allogenic haematopoietic stem cell transplantation in adult patients: a single-centre study. Nephrol Dial Transplant 2009;25;624–7.
Mayumi, H, Umesue, M, Nomoto, K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996;195;129–39.
Brodsky, RA, Petri, M, Smith, BD, Seifter, EJ, Spivak, JL, Styler, M, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129;1031–5.
Luznik, L, Bolanos-Meade, J, Zahurak, M, Chen, AR, Smith, BD, Brodsky, R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115;3224–30.
Kanakry, CG, Tsai, HL, Bolanos-Meade, J, Smith, BD, Gojo, I, Kanakry, JA, et al. Single-agent GVHD prophylaxis with post-transplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 2014;124; 3817–27.
Alousi, AM, Brammer, JE, Saliba, RM, Andersson, B, Popat, U, Hosing, C, et al. Phae II trail of graft-versus-host disease prophylaxis with post-tranplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Tranplant 2015;21;906–12.
Mielcarek, M, Furlong, T, O’Donnell, PV, Storer, BE, McCune, JS, Storb, R, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 2016;127;1502–8.
Carnevale-Schianca, F, Caravelli, D, Gallo, S, Coha, V, D’Ambrosio, L, Vassallo, E, et al. Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. Biol Blood Marrow Transplant 2017;23;459–66.
Moiseev, IS, Pirogova, OV, Alyanski, AL, Babenko, EV, Gindina, TL, Darskaya, EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant 2016;22;1037–42.
Ruggeri, A, Labopin, M, Bacigalupo, A, Afanasyev, B, Cornelissen, JJ, Elmaagacli, A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol 2018;11;40.
Battipaglia, G, Labopin, M, Kröger, N, Vitek, A, Afansyev, B, Hligendorf, I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 2019;134;892–9.
Bolanos-Meade, J, Reshef, R, Fraser, R, Fei, M, Abhyankar, S, Al-Kadhimi, Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 2019;6;e132–e43.
Al-Homsi, AS, Goodyke, A, McLane, M, Abdel-Mageed, S, Cole, K, Muilenburg, M, et al. Post-Tranplatation cyclophophamide and ixazomib combination rescues mice subjected to experimental graft-versus-host disease and is superior to either agent alone. Biol Blood Marrow Transplant 2017;23; 255–61.
Al-Homsi, AS, Cole, K, Muilenburg, M, Goodyke, A, Abidi, M, Duffner, U, et al. Calcineurin and mTOR inhibitor-free post-transplantation cyclophosphamide and bortezomib combination for graft-versus-host disease prevention after peripheral blood allogeneic hematopoietic stem cell transplantation: a phase I/II study. Biol Blood Marrow Transplant 2017;23; 1651–7.
Lee, CJ, Savani, BN, Mohty, M, Labopin, M, Ruggeri, A, Schmid, C, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102;1810–22.
Korngold, R, Sprent, J. T cell subsets and graft-versus-host disease. Transplantation 1987;44;335–9.
Zhang, C, Todorov, I, Zhang, Z, Liu, Y, Kandeel, F, Forman, S, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107;2993–3001.
Bertaina, A, Merli, P, Rutella, S, Pagliara, D, Bernardo, ME, Masetti, R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with non-malignant disorders. Blood 2014;124;822–6.
Balashov, D, Shcherbina, A, Maschan, M, Trakhtman, P, Skvortsova, Y, Shelikhova, L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant 2015;21;1955–62.
Bertaina, A, Zecca, M, Buldini, B, Sacchi, N, Algeri, M, Saglio, F, et al. Unrelated donor vs HLA-haploidentical alpha/beta T-cell-and B-cell-depleted HSCT in children with acute leukemia. Blood 2018;132;2594–607.
Kanate, AS, Mussetti, A, Kharfan-Dabaja, MA, Ahn, KW, DiGilio, A, Beitinjaneh, A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 2016;127;938–47.
McCurdy, SR, Kanakry, JA, Showel, MM, Tsai, HL, Bolanos-Meade, J, Rosner, GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015;125; 3024–31.
Ghosh, N, Karmali, R, Rocha, V, Ahn, KW, DiGilio, A, Hari, PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol 2016;34;3141–9.
Bashey, A, Zhang, X, Sizemore, CA, Manion, K, Brown, S, Holland, HK, et al. T-cell replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donot transplantation. J Clin Oncol 2013;31;130–1316.
Raiola, AM, Dominietto, A, di Garzia, C, Lamparelli, T, Gualandi, F, Ibatici, A, et al. Unmanipulated haploidentical transplants comapared to with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014;20;1573–9.
Huang, XJ, Liu, DH, Liu, KY, Xu, LP, Chen, H, Han, W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38;291–7.
Di Bartolomeo, P, Santarone, S, De Angelis, G, Picardi, A, Cudillo, L, Cerretti, R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013;121;849–57.
Wang, Y, Liu, DH, Xu, LP, Liu, KY, Chen, H, Chen, YH, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011;17;821–30.
Grewal, SS, Barker, JN, Davies, SM, Wagner, JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101;4233–44.
Rocha, V, Labopin, M, Sanz, G, Arcese, W, Schwerdtfeger, R, Bosi, A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351;2276–85.
Eapen,M, Wagner, JE. Transplant outcomes in acute leukemia (I). Semin Hematol 2010;47;46–50.
Atsuta, Y, Morishima, Y, Suzuki, R, Nagamura-Inoue, T, Taniguchi, S, Takahashi, S, et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant 2012;18;780–7.
Kishi, Y, Kami, M, Miyakoshi, S, Kanda, Y, Murashige, N, Teshima, T, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 2005;80;34–40.
Miyakoshi, S, Yuji, K, Kami, M, Kusumi, E, Kishi, Y, Kobayashi, K, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004;10;3586–92.
Terakura, S, Kuwatsuka, Y, Yamasaki, S, Wake, A, Kanda, J, Inamoto, Y, et al. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant 2017;52;1261–7.
Bejanyan, N, Rogosheske, J, DeFor, TE, Lazaryan, A, Arora, M, Holtan, SG, et al. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free graft-versus-host disease prophylaxis for reduced-intensity conditioning umbilical cord blood transplantation. Biol Blood Marrow Transplant 2016;22;2025–30.
Ponce, DM, Eapen, M, Sparapani, R, O’Brien, TA, Chan, KW, Chen, J, et al. In vivo T cell depletion with myeloablative regimens on outcomes after cord blood transplantation for acute lymphoblastic leukemia in children. Biol Blood Marrow Transplant 2015;21;2173–9.
Lindemans, CA, Chiesa, R, Amrolia, PJ, Rao, K, Nikolajeva, O, de Wildt, A, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014;123;126–32.
Pascal, L, Tucunduva, L, Ruggeri, A, Blaise, D, Ceballos, P, Chevallier, P, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood 2015;126;1027–32.
Zheng, C, Luan, Z, Fang, J, Sun, X, Chen, J, Li, CK, et al. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies. Biol Blood Marrow Transplant 2015;21;707–12.
Chen, YB, Wang, T, Hemmer, MT, Brady, C, Couriel, DR, Alousi, A, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant 2017;52;400–8.
Ruggeri, A, Labopin, M, Sanz, G, Piemontese, S, Arcese, W, Bacigalupo, A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 2015;29;1891–900.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Tegla, C., Choi, J., Abdul-Hay, M. et al. Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults. Clin Hematol Int 2, 5–12 (2020). https://doi.org/10.2991/chi.d.200115.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.200115.001